The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges
Abstract
Continuous subcutaneous (SC) infusion of the dopamine agonist apomorphine was shown in retrospective studies to improve drug‐induced dyskinesias in Parkinson's disease (PD). We prospectively assessed the antidyskinetic effect of continuous SC apomorphine therapy using subjective and objective measures, and sought to determine whether any observed dyskinesia reduction could be corroborated using single‐dose dopaminergic challenges. Twelve PD patients with on–off fluctuations and disabling dyskinesias who were scheduled to start apomorphine pump treatment underwent acute levodopa and apomorphine challenges at baseline and 6 months later. Video recordings involving motor tasks were rated blindly by two independent raters using modified AIMS and Goetz dyskinesia scales. At 6 months, mean apomorphine dose was 75.2 mg per day and the mean l‐dopa dose had been reduced by 55%. Daily off time in patients' diaries was reduced by 38% (2.4 hours). The l‐dopa challenges showed a reduction of 44% in AIMS and 40% in Goetz scores (both P < 0.01). Apomorphine challenges showed a reduction of 39% in AIMS and 36% in Goetz scores (both P < 0.01). Patients' self‐assessment scores reflected these significant changes. Dyskinesia improvement correlated with reduction in oral medication and with the final apomorphine dose (P < 0.05). This prospective study confirms marked dyskinesia reduction on continuous subcutaneous apomorphine therapy, paralleled by reduced dyskinesias during dopaminergic challenge tests. Our findings support the concept that replacement of short‐acting oral antiparkinsonian medication with continuous dopamine receptor stimulation may reverse, at least partially, the sensitization process believed to mediate the development of drug‐induced dyskinesias in PD. © 2004 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Self-citationRecent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Electrical Stimulation of the Subthalamic Nucleus in Advanced Parkinson's Disease
Limousin, P., Krack, P., Pollak, P., Benazzouz, A., Ardouin, C., Hoffmann, D., & Benabid, A.-L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391603 · Cited by 1,853
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa000827 · Cited by 1,514
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Irreversible motor impairment in young addicts ? ephedrone, manganism or both?
Sikk, K., Taba, P., Haldre, S., Bergquist, J., Nyholm, D., Zjablov, G., Asser, T., & Aquilonius, S.-M. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00818.x · Cited by 665
Kumar, R., Lozano, A. M., Kim, Y. J., Hutchison, W. D., Sime, E., Halket, E., & Lang, A. E. (1998) · Neurology · doi:10.1212/wnl.51.3.850 · Cited by 634
SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS
Stibe, C. M. H., Kempster, P. A., Lees, A. J., & Stern, G. M. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91193-2 · Cited by 323
Self-citationSubthalamic DBS replaces levodopa in Parkinson’s disease: Two-year follow-up
Vingerhoets, F. J. G., Villemure, J.-G., Temperli, P., Pollo, C., Pralong, E., & Ghika, J. (2002) · Neurology · doi:10.1212/wnl.58.3.396 · Cited by 314
Subcutaneous apomorphine in the treatment of Parkinson's disease.
Frankel, J. P., Lees, A. J., Kempster, P. A., & Stern, G. M. (1990) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.53.2.96 · Cited by 306
Self-citationGoetz, C. G., Stebbins, G. T., Shale, H. M., Lang, A. E., Chernik, D. A., Chmura, T. A., Ahlskog, J. E., & Dorflinger, E. E. (1994) · Movement Disorders · doi:10.1002/mds.870090403 · Cited by 276
Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets
Nyholm, D., Askmark, H., Gomes–Trolin, C., Knutson, T., Lennernäs, H., Nyström, C., & Aquilonius, S.-M. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200305000-00010 · Cited by 236
Manson, A. J., Turner, K., & Lees, A. J. (2002) · Movement Disorders · doi:10.1002/mds.10281 · Cited by 226
Self-citationColzi, A., Turner, K., & Lees, A. J. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.5.573 · Cited by 225
Self-citationContinuous dopamine-receptor stimulation in early Parkinson's disease
Olanow, C. W., Schapira, A. H. V., & Rascol, O. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00030-6 · Cited by 208
Hughes, A. J., Bishop, S., Kleedorfer, B., Turjanski, N., Fernandez, W., Lees, A. J., & Stern, G. M. (1993) · Movement Disorders · doi:10.1002/mds.870080208 · Cited by 204
Self-citationLevodopa Withdrawal After Bilateral Subthalamic Nucleus Stimulation in Advanced Parkinson Disease
Molinuevo, J. L., Valldeoriola, F., Tolosa, E., Rumià, J., Valls-Solé, J., Roldán, H., & Ferrer, E. (2000) · Archives of Neurology · doi:10.1001/archneur.57.7.983 · Cited by 202
Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up
Pietz, K., Hagell, P., & Odin, P. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.5.709 · Cited by 200
Piccini, P., Weeks, R. A., & Brooks, D. J. (1997) · Annals of Neurology · doi:10.1002/ana.410420508 · Cited by 177
Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
Chase, T. N., & Oh, J. D. (2000) · PubMed · Cited by 164
Continuous dopamine-receptor stimulation in advanced Parkinson's disease
Nutt, J. G., Obeso, J. A., & Stocchi, F. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00029-x · Cited by 157
Long-term follow up of subthalamic nucleus stimulation in Parkinson’s disease
Romito, L. M., Scerrati, M., Contarino, M. F., Bentivoglio, A. R., Tonali, P., & Albanese, A. (2002) · Neurology · doi:10.1212/wnl.58.10.1546 · Cited by 148
Ten-year follow-up of three different initial treatments in de-novo PD
Lees, A. J., Katzenschlager, R., Head, J. A., & Ben‐Shlomo, Y. (2001) · Neurology · doi:10.1212/wnl.57.9.1687 · Cited by 143
Self-citationAutomatic assessment of levodopa‐induced dyskinesias in daily life by neural networks
Keijsers, N., Horstink, M. W. I. M., & Gielen, S. C. A. M. (2002) · Movement Disorders · doi:10.1002/mds.10310 · Cited by 139
Engber, T. M., Susel, Z., Juncos, J. L., & Chase, T. N. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90790-5 · Cited by 133
Parkin, S., Gregory, R., Scott, R., Bain, P., Silburn, P., Hall, B., Boyle, R., Joint, C., & Aziz, T. (2002) · Movement Disorders · doi:10.1002/mds.10186 · Cited by 133
Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson’s disease
Fraix, V., Pollak, P., Blercom, N. V., Xie, J., Krack, P., Koudsié, A., & Benabid, A. (2000) · Neurology · doi:10.1212/wnl.55.12.1921 · Cited by 132
Long‐term duodenal infusion of levodopa for motor fluctuations in parkinsonism
Sage, J. I., Trooskin, S. Z., Sonsalla, P. K., Heikkila, R. E., & Duvoisin, R. C. (1988) · Annals of Neurology · doi:10.1002/ana.410240116 · Cited by 120
Cedarbaum, J. M., Gandy, S., & MCDOWELL, F. H. (1991) · Neurology · doi:10.1212/wnl.41.5.622 · Cited by 108
Kaňovský, P., Kubová, D., Bareš, M., Hortová, H., Streitová, H., Rektor, I., & Znojil, V. (2002) · Movement Disorders · doi:10.1002/mds.1276 · Cited by 99
LISURIDE INFUSION PUMP: A DEVICE FOR THE TREATMENT OF MOTOR FLUCTUATIONS IN PARKINSON'S DISEASE
Obeso, J. A., Luquín, M. R., & Martínez‐Lage, J. M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92929-6 · Cited by 98
Levodopa‐induced dyskinesias in Parkinson's disease: Is sensitization reversible?
Bejjani, B.-P. W., Arnulf, I., Demeret, S., Damier, P., Bonnet, A., Houéto, J., & Agid, Y. (2000) · Annals of Neurology · Cited by 82
Fox, S. H., Henry, B., Hill, M. P., Peggs, D., Crossman, A. R., & Brotchie, J. M. (2001) · Movement Disorders · doi:10.1002/mds.1148 · Cited by 82
Clinical Usefulness of Apomorphine in Movement Disorders
Colosimo, C., Merello, M., & Albanese, A. (1994) · Clinical Neuropharmacology · doi:10.1097/00002826-199406000-00004 · Cited by 79
An ambulatory dyskinesia monitor
Manson, A. J. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.2.196 · Cited by 79
Self-citationFactors influencing the onset and persistence of dyskinesia in MPTP-treated primates.
Jenner, P. G. (2000) · PubMed · Cited by 77
Itoh, K., Oyanagi, K., Takahashi, H., SATO, T. A., Hashizume, Y., Shimmoto, M., & Sakuraba, H. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<122::aid-ana21>3.0.co;2-9 · Cited by 77
Low-dose olanzapine for levodopa induced dyskinesias
Manson, A. J., Schrag, A. E., & Lees, A. J. (2000) · Neurology · doi:10.1212/wnl.55.6.795 · Cited by 68
Self-citationSuppression of dyskinesias in advanced Parkinson's disease
Schuh, L. A., & Bennett, J. P. (1993) · Neurology · doi:10.1212/wnl.43.8.1545 · Cited by 63
May, P. R. A., Lee, M. A., & Bacon, R. C. (1983) · Clinical Neuropharmacology · doi:10.1097/00002826-198300061-00006 · Cited by 45
Worsening of levodopa-induced dyskinesias by motor and mental tasks
Durif, F., Vidailhet, M., Debilly, B., & Agid, Y. (1999) · Movement Disorders · Cited by 43
Cited by
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Self-citationSignaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., & Li-Hua, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 469
Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., & Goetz, C. G. (2007) · Movement Disorders · doi:10.1002/mds.21475 · Cited by 464
Trenkwalder, C., Kies, B., Rudzinska, M., Fine, J., Nikl, J., Honczarenko, K., Dioszeghy, P., Hill, D., Anderson, T., Myllyla, V., et al. (2011) · Movement Disorders · doi:10.1002/mds.23441 · Cited by 437
Metadata
- Authors
- Katzenschlager, R., Hughes, A., Evans, A., Manson, A. J., Hoffman, M., Swinn, L., Watt, H., Bhatia, K., Quinn, N., & Lees, A. J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2004-09-10
- Volume
- 20
- Issue
- 2
- Pages
- 151-157
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2061460058
- Cited by
- 286
- References
- 42
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.